Search

Your search keyword '"Gluba-Brzózka, Anna"' showing total 42 results
Start Over Author "Gluba-Brzózka, Anna" Search Limiters Available in Library Collection
42 results on '"Gluba-Brzózka, Anna"'

12. The Role of Long Noncoding RNA (lncRNAs) Biomarkers in Renal Cell Carcinoma.

Author

Rysz, Jacek, Konecki, Tomasz, Franczyk, Beata, Ławiński, Janusz, and Gluba-Brzózka, Anna

Subjects
RENAL cell carcinoma, NON-coding RNA, PATHOLOGICAL physiology, LINCRNA, RENAL cancer, BIOMARKERS, DISEASE progression, PLANT growth promoting substances, ONCOGENES
Abstract

Renal cell carcinoma is one of the common cancers whose incidence and mortality are continuously growing worldwide. Initially, this type of tumour is usually asymptomatic. Due to the lack of reliable diagnostic markers, one-third of ccRCC patients already have distant metastases at the time of diagnosis. This underlines the importance of establishing biomarkers that would enable the prediction of the disease's course and the risk of metastasis. LncRNA, which modulates genes at the epigenetic, transcriptional, and post-transcriptional levels, appears promising. The actions of lncRNA involve sponging and sequestering target miRNAs, thus affecting numerous biological processes. Studies have confirmed the involvement of RNAs in various diseases, including RCC. In this review, we focused on MALAT1 (a marker of serious pathological changes and a factor in the promotion of tumorigenesis), RCAT1 (tumour promoter in RCC), DUXAP9 (a plausible marker of localized ccRCC), TCL6 (exerting tumour-suppressive effects in renal cancer), LINC00342 (acting as an oncogene), AGAP2 Antisense1 (plausible predictor of RCC progression), DLEU2 (factor promoting tumours growth via the regulation of epithelial-mesenchymal transition), NNT-AS1 (sponge of miR-22 contributing to tumour progression), LINC00460 (favouring ccRCC development and progression) and Lnc-LSG1 (a factor that may stimulate ccRCC metastasis). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis

Author

Rysz-Górzynska, Magdalena, primary, Gluba-Brzózka, Anna, additional, Sahebkar, Amirhossein, additional, Serban, Maria-Corina, additional, Mikhailidis, Dimitri P., additional, Ursoniu, Sorin, additional, Toth, Peter P., additional, Bittner, Vera, additional, Watts, Gerald F., additional, Lip, Gregory Y. H., additional, Rysz, Jacek, additional, Catapano, Alberico L., additional, and Banach, Maciej, additional

Published
2016
Full Text
View/download PDF

40. Ageing, Age-Related Cardiovascular Risk and the Beneficial Role of Natural Components Intake.

Author

Rysz, Jacek, Franczyk, Beata, Rysz-Górzyńska, Magdalena, and Gluba-Brzózka, Anna

Subjects
CARDIOVASCULAR diseases risk factors, CELLULAR aging, ENDOCARDIUM, HEART conduction system, HEART valves
Abstract

Ageing, in a natural way, leads to the gradual worsening of the functional capacity of all systems and, eventually, to death. This process is strongly associated with higher metabolic and oxidative stress, low-grade inflammation, accumulation of DNA mutations and increased levels of related damage. Detrimental changes that accumulate in body cells and tissues with time raise the vulnerability to environmental challenges and enhance the risk of major chronic diseases and mortality. There are several theses concerning the mechanisms of ageing: genetic, free radical telomerase, mitochondrial decline, metabolic damage, cellular senescence, neuroendocrine theory, Hay-flick limit and membrane theories, cellular death as well as the accumulation of toxic and non-toxic garbage. Moreover, ageing is associated with structural changes within the myocardium, cardiac conduction system, the endocardium as well as the vasculature. With time, the cardiac structures lose elasticity, and fibrotic changes occur in the heart valves. Ageing is also associated with a higher risk of atherosclerosis. The results of studies suggest that some natural compounds may slow down this process and protect against age-related diseases. Animal studies imply that some of them may prolong the lifespan; however, this trend is not so obvious in humans. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC).

Author

Rysz, Jacek, Franczyk, Beata, Ławiński, Janusz, and Gluba-Brzózka, Anna

Subjects
RENAL cell carcinoma, KIDNEY cortex, CHRONIC kidney failure
Abstract

Renal cell carcinomas (RCCs) is a group of various malignant tumours of the renal cortex displaying distinct clinical, morphologic, and genetic features. Clear cell papillary renal cell carcinoma (ccpRCC), belonging to this group, shares morphologic features with both clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) and therefore, more strict diagnostic criteria should be developed to avoid misdiagnosis. Despite overlapping features, ccpRCC has also distinct clinical behaviour, histologic characteristics (morphologic and immunohistochemical), and genomic features. The concepts concerning this tumour are constantly developing since its biological potential and molecular basis remains to be fully unravelled. First reports indicated the presence of ccpRCC in end-stage renal disease, and they underlined the enriched development in this group of patients; however, currently, it is known that such tumours can also occur spontaneously in the normal kidney. Numerous studies have demonstrated that clinical outcomes and prognosis of ccpRCC patients is highly favourable. Till now, no convincing evidence of metastatic ccpRCC or death caused by the disease has been found. Therefore, it is of high importance to correctly differentiate ccpRCC from other subtypes of RCC with a much worse prognosis and to introduce appropriate management. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. The multi-biomarker approach for heart failure in patients with hypertension

Author

Małgorzata Misztal, Agata Bielecka-Dabrowa, Anna Gluba-Brzózka, Marta Michalska-Kasiczak, Jacek Rysz, Maciej Banach, Bielecka-Dabrowa Agata, Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Gluba-Brzózka Anna, Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, Medical University of Lodz, Michalska-Kasiczak Marta, Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Misztal Małgorzata, Chair of Statistical Methods, Faculty of Economics and Sociology, University of Lodz, Rysz Jacek, Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, Medical University of Lodz, and Banach Maciej, Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz

Subjects
Male, Galectin 3, heart failure, Gastroenterology, lcsh:Chemistry, Transforming Growth Factor beta, Natriuretic Peptide, Brain, Natriuretic peptide, lcsh:QH301-705.5, Spectroscopy, biology, Acute-phase protein, General Medicine, Middle Aged, Lipocalins, Computer Science Applications, Biomarker (medicine), Cytokines, Female, Interleukin 1 receptor, type I, Procollagen, medicine.medical_specialty, hypertension, medicine.drug_class, Catalysis, Article, Inorganic Chemistry, Lipocalin-2, Internal medicine, Proto-Oncogene Proteins, medicine, Humans, Physical and Theoretical Chemistry, Cystatin C, Protein Precursors, Molecular Biology, Aged, Receptors, Interleukin-1 Type I, Receiver operating characteristic, business.industry, Tumor Necrosis Factor-alpha, Organic Chemistry, biomarkers, medicine.disease, Peptide Fragments, Procollagen peptidase, Endocrinology, lcsh:Biology (General), lcsh:QD1-999, Heart failure, biology.protein, Syndecan-4, business, Acute-Phase Proteins
Abstract

We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive patients with or without overt heart failure, the incremental predictive value of the following biomarkers was investigated: Collagen III N-terminal propeptide (PIIINP), cystatin C (CysC), lipocalin-2/NGAL, syndecan-4, tumor necrosis factor-α (TNF-α), interleukin 1 receptor type I (IL1R1), galectin-3, cardiotrophin-1 (CT-1), transforming growth factor β (TGF-β) and N-terminal pro-brain natriuretic peptide (NT-proBNP). The highest discriminative value for HF was observed for NT-proBNP (area under the receiver operating characteristic curve (AUC) = 0.873) and TGF-β (AUC = 0.878). On the basis of ROC curve analysis we found that CT-1 &gt, 152 pg/mL, TGF-β &lt, 7.7 ng/mL, syndecan &gt, 2.3 ng/mL, NT-proBNP &gt, 332.5 pg/mL, CysC &gt, 1 mg/L and NGAL &gt, 39.9 ng/mL were significant predictors of overt HF. There was only a small improvement in predictive ability of the multi-biomarker panel including the four biomarkers with the best performance in the detection of HF—NT-proBNP, TGF-β, CT-1, CysC—compared to the panel with NT-proBNP, TGF-β and CT-1 only. Biomarkers with different pathophysiological backgrounds (NT-proBNP, TGF-β, CT-1, CysC) give additive prognostic value for incident HF in hypertensive patients compared to NT-proBNP alone.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results